Clinical value of cordarone as an antiarrhythmic agent.
The antiarrhythmic efficacy of Cordarone was studied in 90 patients (64 men and 26 women) aged 16-76. Cordarone appeared to be efficacious in the treatment of resistant arrhythmias, particularly ventricular extrasystoles and paroxysmal tachycardia in the WPW syndrome. Total disappearance of dysrhythmias was achieved in 40%, and good therapeutic effects in 32% of patients (an overall 72 percent success). Rapid initial loading (800-1200 mg/day) and continuation with a maintenance dose (100-400 mg/day) may be used as an optimal therapy model. Cordarone is well tolerated even with prolonged use. Side-effects necessitated drug withdrawal in 4.4% of patients. It is possible to combine Cordarone with other selected antiarrhythmic drugs in most resistant rhythm disturbances.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D013617:Tachycardia, Supraventricular / Q000188:drug therapy
D000638:Amiodarone